Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
INVO Fertility, Inc. (NASDAQ:IVF) announced Wednesday that its 2025 annual meeting of stockholders has been adjourned and will reconvene on July 23, 2025, at 12:00 pm Eastern Time. The meeting will be held in a virtual format. The announcement comes as the company’s stock trades near its 52-week low of $0.80, with shares currently at $0.86. According to InvestingPro data, the company faces significant financial challenges, with its stock down over 90% in the past six months.
According to a statement based on a recent SEC filing, stockholders had previously met on June 25, 2025, and voted on several proposals. The meeting was initially adjourned to July 9, 2025, to address an outstanding proposal. On Wednesday, the company’s chief executive officer, acting as chairman, further adjourned the meeting to later in July.
The virtual meeting will be accessible to shareholders through the company’s designated online platform.
INVO Fertility’s common stock is listed on The Nasdaq Stock Market under the symbol IVF. The company is incorporated in Nevada and is headquartered in Sarasota, Florida.
This information is based on a press release statement contained in the company’s recent SEC filing.
In other recent news, INVO Fertility, Inc. has announced several significant developments. The company reported amendments to its preferred stock agreements, allowing the holder of its Series C-2 Convertible Preferred Stock to acquire additional shares through cash purchase or by exchanging existing debentures. This move involves the issuance of 1,800 Series C-2 Preferred Stock shares with a total value of $1.8 million. Additionally, INVO Fertility’s stockholders approved key proposals during its annual meeting, including the election of board members and the ratification of M&K CPAs PLLC as the independent public accountant for the fiscal year ending December 31, 2025.
Moreover, INVO Fertility received a patent allowance for a modified version of its INVOcell device, extending intellectual property protection through 2040. The patent, titled "Intravaginal Culture Incubation Container and Method," simplifies the device design based on feedback from embryologists. Furthermore, the company expanded its telehealth services at the Wisconsin Fertility Institute, allowing virtual consultations across nine additional states. This expansion aims to improve access to fertility care for individuals in rural or underserved areas. These developments highlight INVO Fertility’s ongoing efforts to enhance its financial structure, technological offerings, and service accessibility.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.